Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=14 A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
Healthy
Primary: Plasma Concentration of Zavegepant at 30 Minutes Post-dose on Day 1 of Period 1- Tasso Device Versus (vs.) Standard Venous Phlebotomy — 16.50; 17.87; 2.843; 8.367…
Phase 2 N=157 A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Advanced Primary Liver Cancer · Advanced Biliary Tract Carcinoma
Primary: The Safety and Tolerability — 28; 34; 92; 3 participants
N/A N=64 Triple P forADHD Children's Mothers, Education of Behavioral Problems, and Change in Mothers' Attitude
ADHD, Predominantly Hyperactive - Impulsive · Behavior Problems, Child · ADHD - Attention Deficit Disorder With Hyperactivity
Primary: SDQ: Strengths and Difficulties Questionnaire SDQ — 8.22; 7.71; 6.78; 7.97 score on a scale
N/A N=240 PROSPECTIVE EVALUATION OF HEARTFOCUS
Cardiac Disease
Primary: The Left Ventricular Size (Qualitative Visual Assessment) — 100; 100 Percentage of scans obtained (%)
Phase 4 N=5,052 Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
Acute Coronary Syndrome · Coronary Artery Disease
Primary: Time-to-event: All-cause Mortality — 447.337; 445.196 days
N/A N=67 SAFE Workplace Intervention for People With IDD
Communicable Diseases · Prevention · Workplace Intervention
Primary: Infectious Airborne Disease Knowledge and Preventative Behaviors Outcomes — .61; .71; .72; .65 score on a scale — p=0.3094
Phase 2 N=25 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Hemolytic Disease of the Fetus and Newborn
Primary: Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 2; 4; 4 Participants
N/A N=34 Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Pilot RCT
Bipolar Disorder
Primary: Client Satisfaction Questionnaire-8 (CSQ-8) — 28.00; 26.20 score on a scale
N/A N=184 Brief Cognitive Behavioral Therapy for Chronic Pain to Improve Functioning Among Veterans
Musculoskeletal Pain · Pain
Primary: Brief Pain Inventory -- Interference Subscale (BPI-I) to Assess 12 Week Follow-up — 4.58; 5.35 score on instrument — p=0.026
Phase 3 N=249 HEALEY ALS Platform Trial - Regimen G DNL343
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R-Slope — -0.88; -0.84 Percent change
N/A N=145 Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
Coronary Artery Disease · Myocardial Infarction
Primary: Percentage of Participants Who Experienced Freedom From Major Adverse Cardiac Events (MACE) Within 30 Days Post-procedure — 98.6 Percentage of participants
N/A N=1,000 ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
Phase 4 N=33 Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection
Pain, Postoperative · Lung Diseases
Primary: Change in Visual Analogue Scale (VAS) Pain Score — 4.94; 7.50; 4.57; 6.25 scores on a scale
N/A N=8 A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI
Mild Cognitive Impairment · Memory Disorders · Memory Loss
Primary: Assess the Feasibility of MFE-HD-tDCS Plus Simultaneous Computerized CT as a Viable Intervention by Measuring Consent Rates and Treatment Completion — 4; 4; 4; 4…